NCT00598091 - A Phase I/Expansion Study of Dasatinib | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

May 31, 2012

Conditions

Refractory Solid TumorsPancreatic Adenocarcinoma

Interventions

DRUG

gemcitabine

1000mg/m2, Days 1, 8, 15

DRUG

dasatinib

50mg, PO, QD

DRUG

gemcitabine

1000mg/m2, days 1, 8, 15

DRUG

dasatinib

50mg, PO, BID

Trial Locations (3)

UNC Lineberger, Comprehensive Cancer Center, Chapel Hill

Duke University Medical Center, Durham

Wake Forest Baptist Medical Center, Winston-Salem